Undisclosed Platform Programs

About Zag Bio

Zag Bio is an early-stage biotech developing a first-in-class platform of thymus-targeted bifunctional antibodies to treat autoimmune diseases. Their technology aims to harness the body's natural process of central tolerance by delivering specific self-antigens to the thymus, thereby generating antigen-specific regulatory T cells (Tregs) that can home to diseased tissues and suppress inflammation. This approach promises a precise, potent, and potentially durable therapeutic effect without the broad immunosuppression associated with current treatments. The company is currently in the preclinical stage, building its pipeline and platform.

Therapeutic Areas

Other Autoimmune Diseases Drugs